News und Analysen
10 Stunning Numbers You Need to Know About Breast Cancer
October is breast cancer awareness month. Of course, for many American families, there's no need for a month to be designated to remember breast cancer. They're more than aware of the disease....
The Most Disappointing Marijuana Stock Plunged Once Again Last Week
The legal-marijuana industry is growing at an incredible pace, which is a big reason why investors seemingly can't get enough of pot stocks. According to Marijuana Business Daily's latest report,....
Trump Cuts Cost-Sharing Subsidies, but It Won't Matter to Insurers
Donald Trump campaigned for president on a platform that includes repealing and replacing the Affordable Care Act, or Obamacare. However, Congress has failed to get a plan to his desk so far,....
What's Powering Johnson & Johnson's Impressive Quarterly Earnings?
Johnson & Johnson (NYSE: JNJ) surprised investors with better-than-hoped-for top-line and bottom-line performance in the third quarter, and that news sent shares soaring on Tuesday. The....
What's Powering Johnson & Johnson's Impressive Quarterly Earnings?
Johnson & Johnson (NYSE: JNJ) surprised investors with better-than-hoped-for top-line and bottom-line performance in the third quarter, and that news sent shares soaring on Tuesday. The....
3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report
Johnson & Johnson (NYSE: JNJ) often kicks things off for the healthcare sector with the release of its quarterly earnings, and once again, the largest healthcare company by market cap....
3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report
Johnson & Johnson (NYSE: JNJ) often kicks things off for the healthcare sector with the release of its quarterly earnings, and once again, the largest healthcare company by market cap....
A Tiny Upstart Takes Aim at Robotic Surgery
Intuitive Surgical's (NASDAQ: ISRG) robots enjoy a near monopoly in hospitals, but that could change following last week's FDA approval of TransEnterix's (NYSEMKT: TRX) Senhance. Senhance is a....
A Tiny Upstart Takes Aim at Robotic Surgery
Intuitive Surgical's (NASDAQ: ISRG) robots enjoy a near monopoly in hospitals, but that could change following last week's FDA approval of TransEnterix's (NYSEMKT: TRX) Senhance. Senhance is a....
A Tiny Upstart Takes Aim at Robotic Surgery
Intuitive Surgical's (NASDAQ: ISRG) robots enjoy a near monopoly in hospitals, but that could change following last week's FDA approval of TransEnterix's (NYSEMKT: TRX) Senhance. Senhance is a....
UnitedHealth Looks Beyond Obamacare for Growth
Healthcare reform has been a priority among lawmakers in Congress, but they've thus far failed in their efforts to get rid of the Affordable Care Act. Health-insurance company UnitedHealth Group....
UnitedHealth Looks Beyond Obamacare for Growth
Healthcare reform has been a priority among lawmakers in Congress, but they've thus far failed in their efforts to get rid of the Affordable Care Act. Health-insurance company UnitedHealth Group....
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
Ziopharm Oncology, Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) are both clinical-stage biotechs that could make you rich, but they'll need to carry at least one of their new....
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
Ziopharm Oncology, Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) are both clinical-stage biotechs that could make you rich, but they'll need to carry at least one of their new....
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
Ziopharm Oncology, Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) are both clinical-stage biotechs that could make you rich, but they'll need to carry at least one of their new....
The Country's Biggest Insurer Got Even Bigger in Q3
UnitedHealth Group (NYSE: UNH) is the largest health insurer in the country, and strong financial results in the third quarter show the company's still growing in spite of its decision last year....
The Country's Biggest Insurer Got Even Bigger in Q3
UnitedHealth Group (NYSE: UNH) is the largest health insurer in the country, and strong financial results in the third quarter show the company's still growing in spite of its decision last year....
Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today
Shares of surprise biopharma AVEO Pharmaceuticals (NASDAQ: AVEO) dropped over 16% today on nearly twice the daily average trading volume without any major news story breaking. What's going on?....
Johnson & Johnson Q3 2017 Earnings Conference Call Transcript (JNJ)
Johnson & Johnson (NYSE: JNJ)Image source: The Motley Fool.Q3 2017 Earnings Conference CallOctober 17, 2017, 8:30 a.m. ETContinue readingSource: Fool.com
Johnson & Johnson Q3 2017 Earnings Conference Call Transcript (JNJ)
Johnson & Johnson (NYSE: JNJ)Image source: The Motley Fool.Q3 2017 Earnings Conference CallOctober 17, 2017, 8:30 a.m. ETContinue readingSource: Fool.com
Johnson & Johnson Jumps on Pharma Strength
Johnson & Johnson (NYSE: JNJ) has been a behemoth in the U.S. healthcare space for decades. Yet as a mature company, J&J faces the inevitable challenge of finding ways to keep its growth....
Johnson & Johnson Jumps on Pharma Strength
Johnson & Johnson (NYSE: JNJ) has been a behemoth in the U.S. healthcare space for decades. Yet as a mature company, J&J faces the inevitable challenge of finding ways to keep its growth....
Why TransEnterix Stock Is Soaring Today
Shares of the robotic-surgery company TransEnterix (NYSEMKT: TRXC) rose by as much as 69% today in early morning trading. This small-cap healthcare stock has now appreciated by over 200% since the....
Why TransEnterix Stock Is Soaring Today
Shares of the robotic-surgery company TransEnterix (NYSEMKT: TRXC) rose by as much as 69% today in early morning trading. This small-cap healthcare stock has now appreciated by over 200% since the....
Why Exelixis' Rebound Is Just Getting Started
Exelixis (NASDAQ: EXEL) stock had been in the doldrums. After roaring for much of the first eight months of the year, the biotech's share price sank more than 15% during September. All of that is....